HEALTHEURACTIV
Transparency groups warn half of EU drug trial results not fully disclosed
Transparency groups warn that half of EU drug trial results are not fully disclosed, with around 20% of trials publishing incomplete findings.
Related Signal
Adjacent reporting
- STAT+: A key European clinical trial registry lacks complete and timely results, an analysis finds
- Slow Alzheimer’s diagnoses ‘mean UK patients missing out on experimental treatments’
- STAT+: Pharmalittle: We’re reading about a Lilly obesity drug trial, statistics for an Alzheimer’s drug, and more
- Pharma giant Novo Nordisk discloses breach of clinical trials data
- Trump's new medical report may be missing key information, expert says
- STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts